TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05583695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based music therapy
Description: eight weekly sessions with a combination of both mindfulness and music therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based therapy
Description: eight weekly sessions of mindfulness

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine care
Description: eight weekly sessions of routine care
Study: NCT04658914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Live-attenuated oral human rotavirus vaccine (Rotarix) manufactured by GlaxoSmithKline containing at least 10\^6 CCID50(median cell culture infective doses) of G1P\[8\] rotavirus, RIX4414 strain produced in Vero cells. This vaccine is an oral suspension with a single dose (1.5ml) administered using an oral applicator.
Study: NCT05463523

Intervention type: DEVICE
Intervention: A Real-time Augmented Reality Device with Artificial Intelligence Integration
Description: Patients are diagnosed and treated with the assistance of artificial intelligence, augmented reality and new optical imaging technology, which is different from traditional model.
Study: NCT04658914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Live-attenuated oral human rotavirus vaccine (Rotarix) manufactured by GlaxoSmithKline containing at least 10\^6 CCID50(median cell culture infective doses) of G1P\[8\] rotavirus, RIX4414 strain produced in Vero cells. This vaccine is an oral suspension with a single dose (1.5ml) administered using an oral applicator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent P2-VP8
Description: Trivalent P2-VP8 subunit vaccine manufactured by SK Chemicals containing 90ug of each VP8 antigen derived from P\[4\] (DS-1), P\[6\] (1076), and P\[8\] (Wa) rotavirus strains fused to the P2 epitope from tetanus toxoid and adsorbed to aluminium hydroxide. A single dose (0.5ml) of this vaccine is administered intramuscularly through injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent P2-VP8
Description: Trivalent P2-VP8 subunit vaccine manufactured by SK Chemicals containing 90ug of each VP8 antigen derived from P\[4\] (DS-1), P\[6\] (1076), and P\[8\] (Wa) rotavirus strains fused to the P2 epitope from tetanus toxoid and adsorbed to aluminium hydroxide. A single dose (0.5ml) of this vaccine is administered intramuscularly through injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent P2-VP8
Description: Trivalent P2-VP8 subunit vaccine manufactured by SK Chemicals containing 90ug of each VP8 antigen derived from P\[4\] (DS-1), P\[6\] (1076), and P\[8\] (Wa) rotavirus strains fused to the P2 epitope from tetanus toxoid and adsorbed to aluminium hydroxide. A single dose (0.5ml) of this vaccine is administered intramuscularly through injection.
Study: NCT05285423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Novel technique of Vocal cord Laterlization with Prolene suture.
Description: The procedure will be performed under General anesthesia, preferably with a tracheostomy so that the extent of vocal cord lateralization could be ascertained intraoperatively.
Study: NCT06247904

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be determined from individual MRI-modeled e-field, to achieve approximately motor threshold in the target area.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be close to zero (negligible) since sham coil will be used for the intervention
Study: NCT05766410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK4, 6 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribociclib
Description: CDK4, 6 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: CDK4, 6 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Endocrine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Endocrine therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Endocrine therapy
Study: NCT05981183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation unit (TENS)
Description: The TENS unit will be applied to participants' right ear at the cymba conchae. The dose is dependent on which arm (Intervention A or Intervention B) the participant is assigned to. Participants will undergo 15 minutes of vagal nerve stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation unit (TENS)
Description: The TENS unit will be applied to participants' right ear at the cymba conchae. The dose is dependent on which arm (Intervention A or Intervention B) the participant is assigned to. Participants will undergo 15 minutes of vagal nerve stimulation.
Study: NCT06212973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln
Description: Epinastine Hydrochloride Eye Drops + Simulating Azelastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln
Description: Azelastine Hydrochloride Eye Drops + Simulating Epinastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
Study: NCT04888546

Intervention type: DRUG
Group type: OTHER
Intervention: Anlotinib hydrochloride capsules＋ TQB2450 injection
Description: Anlotinib hydrochloride capsules is a new type of small molecule multi-target tyrosine kinase inhibitor against angiogenesis.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.
Study: NCT06414174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Split septum needleless connector
Description: Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams. Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical valve needleless connector
Description: Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams. Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.
Study: NCT05749328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate
Description: To ensure the safety of the trial, preoperative gastric ultrasound measurements will be performed on all patients to assess their gastric volume. See above for other details
Study: NCT05972746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring with electronic alerts
Description: Patients assigned to this group will receive standard care plus a telemonitoring program.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care
Study: NCT05230784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AirOk Air Purifier
Description: The AirOk purifier nests on a locally developed patented technology that combines HEPA (grade H12) and a novel EGAPA (Effective Granular Adsorbent Particulate Arrestor) to reduce indoor air pollution. The HEPA filter removes all particulate matter up to 0.3 µm in aerodynamic diameter, and the dual stratified EGAPA filter removes other pollutants such as sulfur, nitrous oxide, carbon oxide, volatile organic compounds, allergens, and mold.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Air Filter
Description: Participants in the placebo arm will receive an air purifier with only the EGAPA filter.
Study: NCT06521632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acupoint stimulation
Description: Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 2 hours.
Study: NCT05335096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An AI-chatbot-based mHealth intervention
Description: The participants assigned to the intervention group will get access to an AI-chatbot and can interact with the AI-chatbot at any time. In each round of the interactive communication, the chatbot will provide automated personalized messages containing PrEP, mental health, or HIV testing-related information, motivation and skills based on the participants' answers and will continuously update over time.
Study: NCT06272500

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral administration of receives only oral administration of placebo
Description: receives only oral administration of placebo , with one capsule taken three times a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral administration of compound digestive enzyme capsule
Description: receives only oral administration of compound digestive enzyme capsule, with one capsule taken three times a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral administration of Betaine hydrochloride
Description: receives oral administration of Betaine hydrochloride(BHCL),with one capsule before each meal.
Study: NCT05686291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hybrid volunteer training programme
Description: The volunteer training will consist of a 6-module online course, followed by 5 face-to-face courses, incorporating the key volunteer training components, including Keyes theory, bio-psycho-social model, stress bucket model, recovery model and CHIME model.
Study: NCT06223126

Intervention type: OTHER
Intervention: Combined oral contraception
Description: Women, who want to start taking birth control pills will get a prescription for oral contraception at the discretion of their own attending physician

Intervention type: OTHER
Intervention: Discontinuation of a combined oral contraception
Description: Cessation of the use of combined oral contraceptives
Study: NCT05695144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS active stimulation combined with rTMS sham stimulation
Description: Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS active stimulation combined with tDCS sham stimulation
Description: Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS active stimulation combined with rTMS active stimulation
Description: Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS sham stimulation combined with rTMS sham stimulation
Description: Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward.
Study: NCT05419544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holy Quran Recital effect
Description: The intervention group, listened to holy Quran recitation for 10 minutes twice a day 4 hours a part (10 am and 2 pm) for 2 consecutive days (usually the 2nd and the 3rd day post-operative) after extubation and gaining alertness. We have chosen Surah Al-Rehman because it is considered as the most rhythmic surah of the Quran and the recitation of Qari Abdul Basit is very soothing and effective as he has recited from the deep of the heart. The listing was by a disposable head phones for an I pad for each hospital. The control group received usual care by their nurses.
Study: NCT04861376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pueraria lobata
Description: The dose of Pueraria lobata granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pueraria thomsoni
Description: The dose of Pueraria thomsoni granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will take the same dose as the other two groups.
Study: NCT04164004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire-12
Description: Health status assessment will be completed using the well-validated Kansas City Cardiomyopathy Questionnaire-12 prior to or at the time of heart failure clinic visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kansas City Cardiomyopathy Questionnaire-12
Description: Health status assessment will be completed using the well-validated Kansas City Cardiomyopathy Questionnaire-12 prior to or at the time of heart failure clinic visits.
Study: NCT06178627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.
Description: Different amphotericin B dosage
Study: NCT05307042

Intervention type: DIAGNOSTIC_TEST
Intervention: Deamino Arginine Vasopressin (dDAVP)
Description: After voiding, 40 μg 1-desamino-8-D arginine vasopressin (dDAVP) will be administered intranasally. Throughout the day, urine volume and maximal renal concentrating ability will be determined by measuring osmolality in urine collected at 4 and 6 hours after administration of dDAVP. In addition, water intake, body weight, blood pressure and heart rate will be determined at baseline and 6 hours after administration of dDAVP.
Study: NCT06127628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided scalp block with ropivacaine 0.375%
Description: Scalp block will be performed under USG guidance, using the technique described by Tsan et al. The block needle used will be an echogenic block needle, with a length of 50 mm, and a diameter of 22 G. Trained personnel comprising of the investigators in this study will perform the scalp block. Using ultrasound to identify landmarks, ropivacaine 0.375% will be administered in volumes of 1.5 ml to 3 ml. The nerves targeted will be the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater auricular, lesser occipital, greater occipital and third occipital nerves.
Study: NCT05231239

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS : Transcranial direct current stimulation
Description: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS : Transcranial direct current stimulation
Description: Transcranial direct current stimulation
Study: NCT05856981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADU-1805
Description: anti-SIRPα monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADU-1805
Description: anti-SIRPα monoclonal antibody
Study: NCT06178627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.
Description: Different amphotericin B dosage
Study: NCT05856981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Keytruda
Study: NCT06208137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health monitoring and regular return follow-up reminders
Description: Health monitoring \& reminders for blood tests and follow-up visits until 1 year post-transplant
Study: NCT05563064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karika Syrup
Description: To evaluate the effects of Karika syrup on complete blood count specifically thrombocytes (platelets) collected from blood samples of patients after treatment of 15 days long period.
Study: NCT05464823

Intervention type: OTHER
Group type: OTHER
Intervention: Molecular Functional Portrait
Description: Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test
Study: NCT05335096

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: An attention-chatbot-based mHealth intervention
Description: The participants assigned to the control group will get access to an attention-chatbot and can interact with the attention-chatbot at any time. In each round of the interaction, the chatbot will provide pre-scripted time-attention health education messages to the participants.
Study: NCT06279832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trascriptomic profiling
Description: The mutational and copy number analyses will be complemented by transcriptomic profiling. RNA will be extracted from FFPE samples using miRNAeasy FFPE kit (Qiagen) and checked for quality and quantify by 2100 Bioanalyzer instrument (Agilent) and Qubit Fluorometer (ThermoFisher), respectively. Transcriptome analyses will be performed by RNA-seq. We will apply total RNAseq using the Illumina® TruSeq Stranded Total RNA workflow that provides a solution allowing the detection of whole transcriptome, splicing variants, and transcript fusions of human RNA isolated from FFPE samples. Libraries will be run using the Illumina's Novaseq6000 system, with a least 50 millions of reads/sample, the minimum read depth for the correct evaluation of low expressed transcripts.
Study: NCT06575543

Intervention type: RADIATION
Intervention: CT
Description: 3D CT scan have been used to evaluate the tunnels location after ACL reconstruction, as they can provide excellent perspective of the tunnel aperture, good visualization of bony structure and shape of the intercondylar notch, that preclude the use of a conventional 2-dimensional CT scan for measurement of the ACL tunnels location

Intervention type: RADIATION
Intervention: CT
Description: 3D CT scan have been used to evaluate the tunnels location after ACL reconstruction, as they can provide excellent perspective of the tunnel aperture, good visualization of bony structure and shape of the intercondylar notch, that preclude the use of a conventional 2-dimensional CT scan for measurement of the ACL tunnels location
Study: NCT04599465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed dose combination (FDC) tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablets for oral administration.
Study: NCT05177185

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal-sparing
Description: Dose constraint placed on hippocampi to minimize dose to hippocampi, while maintaining target coverage (at least 98% of brain metastasis volume must receive 100% of prescription dose).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Description: Stereotactic radiosurgery (SRS) with prescription dose determined based on size of brain metastasis; 21 or 24 Gy in a single fraction if less than or equal to 20 mm, 18Gy in a single fraction in 21 - 30 mm, 15 Gy in a single fraction or 30 Gy in 5 fractions if 31 - 40 mm (physician discretion).
Study: NCT05419934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR therapy
Description: Children will receive an EMDR psychotherapy comprising 8 treatment phases. As the treatment progresses, the child will proceed to desensitize the events of adversity experienced.~Phase 1 and 2, before the desensitization phases:~1. History of the patient (collection of anamnesis)~2. Securing the patient, preparing for the desensitization phases~   Desensitization phases, to be repeated for each traumatic event to be desensitized:~3. Evaluation of the target to be treated~4. Desensitization~5. Installation of positive beliefs~6. Body scanner (verification of body non-response)~7. Closure, verification that the patient is in a stable emotional state allowing him to leave the session~   Reassessment phase, to be repeated for each traumatic event that has been desensitized:~8. Reassessment of the traumatic target, verification of complete desensitization.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Routine Care
Description: Children in the routine care group receive psychological monitoring administered by the Lenval Foundation (CHU de Nice - France) within the Pediatric Psychotrauma Assessment Center (Centre d'évaluation du psychotraumatisme pédiatrique - CE2P). The proposed treatment is a psychological follow-up associated with relational support psychotherapy